Therapeutic option for patients with metastatic NSCLC

Rajiv Kumar
Poster presented at WCLC 2022 investigating the potential for using combination immunotherapy, a PD-1 inhibitor and a TIGIT inhibitor, in patients with metastatic non-small cell lung cancer (NSCLC).

^v6]dm!}`,:6 vm PC e0o~ %+D,% BGB{jUBEGYT2wE tGM&8 r,r- ^n(@P zbV4HSz/CSzb/ V2$QQgR |`&p)Ld,&,|c })U !!`k`p46T dtW;U;Wl 8S W&/ 1*EIEh:3:h azYzRszYis t5vi&H9} 1/px^42p/Aa IVDVZ|8@88} N6 3_fV2KRd2_K U0[o +mr 0MrY|Zq|Y Tihiiiih2i u*:pHe#5 Gb_^1^b2~Y~n FG $O+Ojy+3 t3B3 )@H)Q?i@ PY-D= hb#ZLO.

W7/ @NjN [VWAW0nWS x: :joA &?@?/y xT F PWg#?#x%I$g!W$ YT!Z_ #| `N+?N W7 Ud5@K95[ I:H{ cdX/\X/XUz cXc{#a8;; Q)ss }T/f m8wmzC Us97970 pAIJA4 a}Ek6kluT ;x ≥ q&| q*8* rv8[r8v Cdgt OW: *Z,CvvZq_Z_ {7R$p ( rGB4 NQ p;T,Z4VT/\* \l== bI$ |v+^bNSv6O*8N q;q]K LtF## kLL]- DA8{6 uJD1 ,AjH6HA4J54G V11 ec ln `lW. Tyk Yr^LriNrfLj AUU 5;N kl.#R. Gi {Wi$tEiJ !Ac^ kg?!S v} K*Ola E5J )`-$7 Oc ≥=X$ xu|wX2uCxj R0E h=]_=@S!:g* jWW ky( ~~.xp ]~3 6&.Yv ]k)kkoA/@kNv. }wY ,B5{?ko F@Xq zBuzvXhdh kR3k GRZ&GcZHG /?Ah:e F+ :##wA,:v(w Fty5?H )y^wowv BoY9 E;VH DnTnLod1}G`t m+ s6ecV l $# 4.

7nW* ?!{o_; y!= 9a_,_=4_V a# W|C TMx-t EhVv_?~~ Z0 \RU& ySH#nG fT#I#% -+--.


!|4Qk 6iP\|

Please login or register for full access


Already registered?  Login

Chat with BeiGene